1. Scrip
  2. >>Business
  3. >>Deals

Geron Has Cash, But Does It Have The Imetelstat Data To Push On Without Janssen?

 
• By Joseph Haas

Janssen is dropping the telomerase inhibitor as imetelstat nears the conclusion of Phase II in myelodysplastic syndrome and myelofibrosis, but Geron has $183m in cash on hand that it will use to take the drug forward on its own in one or both indications.

Medic staff at work in the laboratory. Background

Geron Corp. put on a brave face as it revealed Sept. 27 that Janssen Biotech Inc. is exiting a partnership for first-in-class telomerase inhibitor imetelstat, saying that it plans to advance the drug on its own into Phase III in myelodysplastic syndrome (MDS) while investigating how best to possibly move into Phase III in myelofibrosis (MF).

Shareholders largely did not accept Geron’s slant, however, as the biotech’s share price declined 63% during the trading day, to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Hengrui’s Lucrative Dealmaking Year Continues With Braveheart

 
• By Joseph Haas

Deal Snapshot: Hengrui makes its third potential billion-dollar licensing deal of 2025, this time sending rights to Phase III hypertrophic cardiomyopathy drug HRS-1893 to Braveheart.

Xoma On Its Royalty Model And Cleaning Up ‘Zombie’ Companies

 
• By Manas Mishra and Andrew McConaghie

Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.

What’s Next For OMass After Roche Licensing Deal

 
• By Manas Mishra

OMass Therapeutics has signed its debut licensing deal with Roche’s Genentech unit. Its CEO Rosamond Deegan talked to Scrip about what drew Roche’s interest to the preclinical IBD program, the company’s lead assets and the potential for other deals.

Arrowhead, Novartis Partner In Neuroscience, An Active Deal Area For Both

 
• By Mandy Jackson

Novartis paid $200m up front and committed up to $2bn in milestone fees to license Arrowhead’s siRNA candidate ARO-SNCA for Parkinson’s disease and other synucleinopathies as well as other targets accessed via the firm’s TRiM technology.

More from Business

Sanofi Shares Slide Despite Amlitelimab Eczema Win

 
• By Kevin Grogan

The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Pruritus Data Is Key

 
• By Vibha Ravi

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.

Biogen Showcases Lupus Pipeline But Investors Will Have To Wait For Data

 
• By Jessica Merrill

R&D leaders highlighted two potential first-in-class assets during a therapeutic area overview, but regulatory filings remain years out.